Sg3 Management, LLC Mirati Therapeutics, Inc. Call Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $369,054 - $548,026	-10,100 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $4.14 Million - $9.9 Million	100,400 Added 994.06%	110,500 $5.01 Million
Q3 2022 May 15, 2023	SELL	$59.5 - $86.7 $5.97 Million - $8.7 Million	-100,400 Reduced 90.86%	10,100 $705,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $600,950 - $875,670	10,100 New	10,100 $705,000
Q4 2021 Feb 15, 2022	SELL	$132.01 - $190.29 $8.78 Million - $12.7 Million	-66,500 Reduced 36.94%	113,500 $16.6 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $23.8 Million - $31.9 Million	180,000 New	180,000 $31.8 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $2.35 Million - $2.93 Million	-16,300 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $16.6 Million - $23.2 Million	-104,700 Reduced 86.53%	16,300 $2.79 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $19.6 Million - $29.1 Million	121,000 New	121,000 $26.6 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.